The low dosage hydrate inhibitors market size is predicted to be worth USD 95.15 billion in 2025 and rise to USD 206.27 ...

RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2025, and provided a ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas.

Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas ...